Overexpression of STC2 has been demonstrated to contribute to poor prognosis or recurrence in colorectal (15), gastric (16) and prostate (17) cancer, as well as neuroblastoma (18) and renal cell carcinoma (8). Here, STC2 is linked to renal cell carcinoma.